Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Show me how to use this page

Biogen Inc. Stock

Price
Target price
€165.76

€165.76

0.680%
1.12
0.680%
€185.69
 
19:39 / Tradegate WKN: 789617 / Symbol: BIIB / Name: Biogen / Stock / Pharmaceuticals / Large Cap /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Biogen Inc. in the next few years
Wizard

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Biogen Inc. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Biogen

sharewise wants to provide you with the best news and tools for Biogen, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push
Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push

Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease

MarketBeat 
0 01:10
Best Healthcare Stocks to Buy in 2026: https://g.foolcdn.com/editorial/images/868943/adaptimmune.jpg
Best Healthcare Stocks to Buy in 2026

Biogen (NASDAQ: BIIB) and Novo Nordisk (NYSE: NVO) represent different opportunities within the healthcare sector: One is a value-oriented play focusing on specialized neurology, while the other is

TheMotleyFool 
0 14.05.26
Why Biogen Stock Was a Winner on Wednesday: https://g.foolcdn.com/editorial/images/867802/two-people-participating-in-a-telehealth-session.jpg
Why Biogen Stock Was a Winner on Wednesday

Prominent biotech Biogen (NASDAQ: BIIB) loomed large on the stock market on Wednesday. It published its latest set of quarterly earnings, and investors greeted the estimates-beating numbers by

TheMotleyFool 
0 30.04.26
Why Biogen Stock Got Mashed on Monday: https://g.foolcdn.com/editorial/images/864251/healthcare-professional-inspecting-charts.jpg
Why Biogen Stock Got Mashed on Monday

Healthcare company Biogen (NASDAQ: BIIB) wasn't looking very healthy on the stock market on Monday. Investors traded out of its shares after learning that the company plans to book a hefty charge in

TheMotleyFool 
0 07.04.26
Why Biogen Stock Sank While the Market Soared on Thursday: https://g.foolcdn.com/editorial/images/863638/person-checking-medicine-on-a-shelf-in-a-pharmacy.jpg
Why Biogen Stock Sank While the Market Soared on Thursday

Bullishness was in the air on the stock market on Tuesday, but you'd hardly know that from the performance of Biogen (NASDAQ: BIIB). The healthcare sector mainstay saw its share price slump by over

TheMotleyFool 
0 01.04.26
Why Biogen Stock Surged Almost 9% Higher on Friday
Why Biogen Stock Surged Almost 9% Higher on Friday

One of the healthier stocks on the market Friday was veteran biotech Biogen (NASDAQ: BIIB). The company unveiled its final set of fundamentals for 2025, and it crushed analyst estimates for both

TheMotleyFool 
0 07.02.26